TRT target testosterone levels: is 'no target' actually good advice?

What did @therestoreclinic actually say?

The creator's core argument is that testosterone replacement therapy shouldn't chase a specific number. Instead, the goal is "symptomatic resolution," meaning roughly 80 to 90% improvement in symptoms like brain fog, energy, sleep, sex drive, and recovery. They pointed out that some men feel great at 700-800 ng/dL, while others feel nothing at those same levels, so the number itself isn't the target, the feeling is.

That's the short version. The longer version is that this is a real clinical philosophy, not a fringe idea invented by a TikTok clinic. Symptom-guided dosing has legitimate support in endocrinology literature, and the creator deserves credit for not simply telling patients to aim for a specific number pulled from thin air.

Does the science back this up?

Mostly, yes, with some important caveats the video skips entirely. The 2018 American Urological Association guidelines and the Endocrine Society's 2018 clinical practice guidelines both acknowledge that testosterone levels should be interpreted alongside symptoms, not in isolation. There is no universally agreed-upon "optimal" level once you're in the normal physiologic range.

A 2020 systematic review by Corona et al. in the Journal of Sexual Medicine confirmed significant interindividual variability in how men respond to TRT, supporting the idea that one man's 750 ng/dL is another man's 500 ng/dL, functionally speaking. Androgen receptor sensitivity, sex hormone-binding globulin levels, and free testosterone fraction all vary between individuals, which means total testosterone is a blunt instrument.

So the symptom-focus is grounded in evidence. But "no target level" as an absolute statement deserves more nuance than this video provides.

What did they get wrong (or right)?

They got the general direction right. Symptom-guided therapy is legitimate, and the specific symptoms they listed, brain fog, energy, sleep quality, libido, and recovery, are genuinely validated outcomes in TRT literature. A 2016 trial by Snyder et al. in the New England Journal of Medicine (the Testosterone Trials) found measurable improvements in sexual function and mood that tracked with symptom reporting, not just serum levels.

Here's where it gets slippery, though. Saying there is "no such thing as a target level" is an oversimplification that could actually harm patients. Most major guidelines do set a rough therapeutic range, typically 400 to 700 ng/dL for maintenance, specifically to reduce cardiovascular and hematologic risk at supraphysiologic levels. Polycythemia, elevated hematocrit, and erythrocytosis risk climb meaningfully when levels push well above physiologic ranges, particularly with injectable testosterone. A man who "feels amazing" at 1,200 ng/dL is not automatically safe there. The creator doesn't mention monitoring hematocrit, PSA, or cardiovascular markers once, and that's a real gap.

What should you actually know?

Symptom-guided TRT is a reasonable framework, but it has to sit alongside laboratory monitoring, not replace it. The idea that feeling better equals being safe is not how regulated medicine works, and any clinic operating on feeling alone is leaving risk unaddressed.

Here's what the evidence actually supports: target ranges exist not to make you feel a certain way but to keep you out of physiologic territory where risk accumulates. The Endocrine Society recommends targeting the mid-normal range, roughly 400 to 700 ng/dL, for most men on TRT. Free testosterone and sex hormone-binding globulin add context total testosterone alone can't provide.

• Hematocrit should be checked at baseline, 3 months, and then annually. Values above 54% are a reason to reduce dose or pause therapy, regardless of how good you feel.
• PSA monitoring matters, especially in men over 40.
• Cardiovascular risk stratification should happen before starting TRT, not after symptoms improve.

A good TRT provider uses symptom improvement as one signal, not the only signal. The video presents half of the clinical picture clearly and drops the other half entirely.